Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies.
Tetef ML, Synold TW, Chow W, Leong L, Margolin K, Morgan R, Raschko J, Shibata S, Somlo G, Yen Y, Groshen S, Johnson K, Lenz HJ, Gandara D, Doroshow JH.
Tetef ML, et al. Among authors: yen y.
Clin Cancer Res. 2001 Jun;7(6):1569-76.
Clin Cancer Res. 2001.
PMID: 11410492
Clinical Trial.